Chenland Nutritionals announces promising results of open labels study on its JadeImmune ingredient
In the clinical study, which has yet to be published, 27 health adults between the ages of 25 and 51 were given 1500 mg of JadeImmune daily for 90 days.
Photo © iStockphoto.com/Eraxion
Chenland Nutritionals Inc. (Irvine, CA) announced the results of a recently completed 90-day open label human clinical trial, investigating the effects of its JadeImmune ingredient, which is based on Jade Screen Powder, an ancient Chinese formula widely used in the Asian countries such as Korea and Japan. In the clinical study, which has yet to be published, 27 health adults between the ages of 25 and 51 were given 1500 mg of JadeImmune daily for 90 days.
Results showed that antibody levels in saliva and blood increased in subjects. Compared to baseline, levels of sIgA and LZM increased by 7.7% and 20.5%, respectively, after 90 days. IgG levels in serum increased by 5.1%. Researchers also observed that inflammatory response was inhibited. Compared to baseline, TNF-α and IL-6 levels decreased by 27.8% and 16.2%, respectively, after 90 days. In addition, NK immune cells increased by 22.8% in blood, compared to baseline, after 90 days.
One month prior to the study, 40.7% (11 of 27) of subjects stated they caught a cold. After 30 and 90 days of the study, 33.3% (9 of 27) and 29.6% (8 of 27), respectively, reported having caught a cold. According to the researchers, this may represent a gradual decline in the incidence of colds. After 90 days, cold symptom scores declined by 7.7%.
To build on and validate these results, Chenland is planning to conduct a double-blind human clinical study this year.
